Apremilast is a small-molecule biologic approved by the US Food and Drug Administration (FDA) for use in plaque psoriasis, psoriatic arthritis, and Behçet disease. Although apremilast is seemingly a less favorable choice for treating psoriasis in the era of injectable biologics, the drug is an important option for patients in the military. In this article, we review on-label indications and off-label uses for apremilast; highlight the importance of apremilast for managing psoriasis in the military population; and propose other patient populations in whom the use of apremilast is favorable. We also present a case report that highlights and embodies the benefit of apremilast for military service members.

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0231DOI Listing

Publication Analysis

Top Keywords

apremilast
7
apremilast relevance
4
military
4
relevance military
4
military apremilast
4
apremilast small-molecule
4
small-molecule biologic
4
biologic approved
4
approved food
4
food drug
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!